Zensun Sci & Tech Co., Ltd. is a research and innovation driven biopharmaceutical company. We develop innovative drugs based on our fundamental scientific discoveries in cardiology and oncology. Focusing on the unmet needs in those two areas, Zensun has developed breakthrough drugs to treat heart failure, breast cancer and other life-threatening diseases.
    Neucardin™ is currently in Phase III clinical trials in China and has completed Phase II clinical trials in China, Australia and the United States. And it has been approved to perform Phase III clinical trials in the US by FDA at the end of 2013, and the international multi-center phase III clinical trial is planning to start in 2015. The therapeutic tumor vaccine: recombinant human ErbB3 fragment (rhErbB3-f) has been developed as a new strategy to cure ErbB2 overexpressed cancer and finished phase I clinical trials. While the other three preclinical drugs represent our new progress in heart failure and oncology research and provide new methods in treatment of these two diseases.
Clinical Trials Recruiting Participants